Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation

Drug Development and Industrial Pharmacy

Volumn 38, Issue 10, 2012, Pages 1230-1239

  Jiang, Tongying ^a   Han, Ning ^a   Zhao, Buwen ^a   Xie, Yuling ^a   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti solvent precipitation; Bioavailability; Dissolution rate; Nanocrystal; Simvastatin; Sonoprecipitation; Stabilizer

Indexed keywords

CARBOXYMETHYLCELLULOSE; MEVINOLIN; NANOCRYSTAL; ORGANIC SOLVENT; SIMVASTATIN;

ANIMAL EXPERIMENT; APPARATUS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRECIPITATION; RAT; SCANNING ELECTRON MICROSCOPY; SONOPRECIPITATION; ULTRASOUND; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMICAL PRECIPITATION; METHANOL; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SIMVASTATIN; SOLUBILITY; SONICATION; TEMPERATURE; WATER; X-RAY DIFFRACTION;

EID: 84862062066     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.645830     Document Type: Article

References (33)

1. Kocbek P, Baumgartner S, Kristl J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 312:179-186.
2. Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. (2009). Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm, 374:106-113.
3. Perrut M, Jung J, Leboeuf F. (2005). Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: Micronization of neat particles. Int J Pharm, 288:3-10. (Pubitemid 39656449)
4. Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. (2010). Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci, 13:589-606.
5. Yu L. (2001). Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev, 48:27-42. (Pubitemid 32454482)
6. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm, 364:64-75.
7. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644. (Pubitemid 47285408)
8. Liversidge GG, Conzentino P. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125, 309-313.
9. Kumar V, Wang L, Riebe M, Tung HH, Prud'homme RK. (2009). Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters. Mol Pharm, 6:1118-1124.
10. Makhlof A, Miyazaki Y, Tozuka Y, Takeuchi H. (2008). Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method. Int J Pharm, 357:280-285.
11. Matteucci ME, Hotze MA, Johnston KP, Williams RO3rd. (2006). Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir, 22:8951-8959. (Pubitemid 44626160)
12. Ruch F, Matijevic E. (2000). Preparation of Micrometer Size Budesonide Particles by Precipitation. J Colloid Interface Sci, 229:207-211. (Pubitemid 30656103)
13. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ et al. (2006). Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm, 323:153-160. (Pubitemid 44397363)
14. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P. (2008). Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm, 70:109-115.
15. Guo Z, Zhang M, Li H, Wang J, Kougoulos E. (2005). Effect of ultrasound on anti-solvent crystallization process. J Cryst Growth, 273, 555-563.
16. Louhi-Kultanen M, Karjalainen M, Rantanen J, Huhtanen M, Kallas J. (2006). Crystallization of glycine with ultrasound. Int J Pharm, 320:23-29. (Pubitemid 44128716)
17. Luque De Castro MD, Priego-Capote F. (2007). Ultrasoundassisted crystallization (sonocrystallization). Ultrason Sonochem, 14, 717-724.
18. Löbenberg R, Amidon GL. (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm, 50:3-12. (Pubitemid 30326685)
19. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65-73. (Pubitemid 38457007)
20. Margulis-Goshen K, Magdassi S. (2009). Formation of simvastatin nanoparticles from microemulsion. Nanomedicine, 5:274-281.
21. Verma S, Gokhale R, Burgess DJ. (2009). A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm, 380:216-222.
22. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22:906-910. (Pubitemid 43282149)
23. Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH. (2005). Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci, 24:441-449. (Pubitemid 40387258)
24. Dong Y, Ng WK, Shen S, Kim S, Tan RB. (2009). Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm, 375:84-88.
25. Raghavan SL, Trividic A, Davis AF, Hadgraft J. (2001). Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm, 212:213-221. (Pubitemid 32119447)
26. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y et al. (2010). Preparation of stable nitrendipine nanosuspensions using the precipitationultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci, 40:325-334.
27. Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. (2009). Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm, 71:109-116.
28. Sharma P, Denny WA, Garg S. (2009). Effect of wet milling process on the solid state of indomethacin and simvastatin. Int J Pharm, 380:40-48.
29. Müller RH, Benita S, Böhm BHL. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publishers; 1998.
30. Qiu Y, Chen Y, Zhang GGZ. Developing solid oral dosage forms: pharmaceutical theory and practice. Burlington: Academic; 2009.
31. Ambike AA, Mahadik KR, Paradkar A. (2005). Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm AQ4 m Res, 22:990-998. (Pubitemid 40898109)
32. Hintz RJ, Johnson KC. (1989). The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm, 51,9-17. (Pubitemid 19087827)
33. Jia L, Wong H, Cerna C, Weitman SD. (2002). Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091-1096. (Pubitemid 34984991)